Cognition Therapeutics/$CGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Ticker
$CGTX
Sector
Primary listing
Employees
14
Headquarters
Website
CGTX Metrics
BasicAdvanced
$111m
-
-$0.25
1.81
-
Price and volume
Market cap
$111m
Beta
1.81
52-week high
$3.83
52-week low
$0.22
Average daily volume
1m
Financial strength
Total debt to equity
1.862
Interest coverage (TTM)
-3,295.46%
Profitability
EBITDA (TTM)
-42.823
Management effectiveness
Valuation
Price to book
3.22
Price to tangible book (TTM)
3.22
Growth
Earnings per share change (TTM)
-65.90%
3-year earnings per share growth (CAGR)
-36.06%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs